The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and Interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.

The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and Interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.

Provided herein are compositions and methods for targeting (e.g., inhibiting or enhancing the activity or expression N of) melanocortin 3 receptor (MC3R) gene, mRNA, and protein for the treatment and/or prevention of eating disorders (e.g., anorexia nervosa, cachexia, etc.), metabolic disorders (e.g., obesity, diabetes, non-alcoholic steatohepatitis, hypertension, etc.), and/or emotional/mental disorders (e.g., depression, anxiety, OCD, PTSD, etc.). In particular, provided herein are MC3R agonists that stimulate MC3R for the treatment/prevention of disorders such as anorexia nervosa and other eating and/or anxiety disorders, MC3R antagonists that inhibit MC3R for the treatment/prevention of obesity and/or other eating/metabolism disorders, and methods of use thereof.

Provided herein are compositions and methods for targeting (e.g., inhibiting or enhancing the activity or expression N of) melanocortin 3 receptor (MC3R) gene, mRNA, and protein for the treatment and/or prevention of eating disorders (e.g., anorexia nervosa, cachexia, etc.), metabolic disorders (e.g., obesity, diabetes, non-alcoholic steatohepatitis, hypertension, etc.), and/or emotional/mental disorders (e.g., depression, anxiety, OCD, PTSD, etc.). In particular, provided herein are MC3R agonists that stimulate MC3R for the treatment/prevention of disorders such as anorexia nervosa and other eating and/or anxiety disorders, MC3R antagonists that inhibit MC3R for the treatment/prevention of obesity and/or other eating/metabolism disorders, and methods of use thereof.

Provided herein are compositions and methods for targeting (e.g., inhibiting or enhancing the activity or expression N of) melanocortin 3 receptor (MC3R) gene, mRNA, and protein for the treatment and/or prevention of eating disorders (e.g., anorexia nervosa, cachexia, etc.), metabolic disorders (e.g., obesity, diabetes, non-alcoholic steatohepatitis, hypertension, etc.), and/or emotional/mental disorders (e.g., depression, anxiety, OCD, PTSD, etc.). In particular, provided herein are MC3R agonists that stimulate MC3R for the treatment/prevention of disorders such as anorexia nervosa and other eating and/or anxiety disorders, MC3R antagonists that inhibit MC3R for the treatment/prevention of obesity and/or other eating/metabolism disorders, and methods of use thereof.

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

The present invention is directed to alpha-MSH analogues for treatment of inflammatory disease.

The present invention is directed to alpha-MSH analogues for treatment of inflammatory disease.